NKGen Biotech to Present at the 2nd International Alzheimer’s Disease & Dementia Conference 2023
SANTA ANA, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics, today announced that they have been invited to give an oral presentation at the 2nd International Alzheimer’s Disease & Dementia Conference 2023 to be held virtually and in-person in Rome, Italy, from June 16–17, 2023.
- SANTA ANA, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics, today announced that they have been invited to give an oral presentation at the 2nd International Alzheimer’s Disease & Dementia Conference 2023 to be held virtually and in-person in Rome, Italy, from June 16–17, 2023.
- Location: Mercure Roma West Viale Eroi di Cefalonia, 301, 00128 Roma RM, Italy
The presentation entitled, “Use of highly enhanced autologous natural killer cells for advanced Alzheimer’s disease,” will be presented by Paul Y. - Song, M.D., Chief Executive Officer of NKGen.
- Dr. Song will focus the presentation on how chronic protein deposition elicits a neuroinflammatory cascade and damage, the potential role of NK cells in reducing proteins as well as neuroinflammation, and discussion of several case studies with preliminary biomarker data.